Novo Nordisk's weight loss drug Wegovy could face Medicare price negotiations next. Meanwhile, Particle Health files an ...

Novo Nordisk CEO Lars Fruergaard Jørgensen is testifying before the Senate Health, Education, Labor and Pension committee on ...

Semaglutide, the underlying drug marketed as Ozempic and Wegovy, works by mimicking a hormone that triggers the body to feel ...

The chief executive of the company behind Ozempic and Wegovy blamed insurers and middlemen for the high costs of weight-loss ...

Novo Nordisk under political pressure over high U.S. drug prices as CEO testifies before Congress. PBMs and limited impact on ...

Patients on semaglutide, the active ingredient in Ozempic and the weight-loss drug Wegovy, were less than half as likely to overdose.

Wegovy is a once-weekly injection approved by the U.S. Food and Drug Administration (FDA) to treat obesity in people 12 and ...

Wegovy and Other New Weight Loss Drugs Actually Work—so What’s Next ... And it’s still only Phase I data, which is explicitly ...

Senator Bernie Sanders (D-VT) pushes for change in Washington as CEO of Novo Nordisk, maker of Ozempic and Wegovy, is under ...

BioAge Labs, a biopharmaceutical startup focused on obesity drugs, is looking to raise nearly $200 million in its recently ...

Shares of BioAge Labs opened 25% above their initial public offering price on Thursday in a strong debut for the weight-loss drug developer against the backdrop of surging investor enthusiasm.

Novo Nordisk CEO Lars Fruergaard Jørgensen testified before the Senate Health, Education, Labor and Pension committee on ...